Navigation Links
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
Date:3/16/2009

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of chronic pain. The development program for this drug candidate was reviewed with the U.S. Food and Drug Administration (FDA) during a successful end-of-Phase II meeting with the FDA on February 19, 2009. As a result of that meeting, we believe we understand the anticipated regulatory pathway for the Phase III program and approval, which we expect will follow a 505(b)2 pathway as discussed with FDA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"In this trial, all of the primary and secondary objectives were met by showing patients could be successfully converted from oral opioids such as OxyContin(R) and from fentanyl patches such as Duragesic(R) to TRANSDUR-Sufentanil, while also showing a reduction in pain scores on our therapy," stated James Brown, President and CEO of DURECT Corporation. "We believe that our small, patient-friendly seven day sufentanil patch would compete effectively in the chronic pain market including both patches and oral opioids."

In addition to the recent Phase IIb study, there have been 9 additional clinical studies performed to date with TRANSDUR-Sufentanil that have involved over 300 patient exposures. These studies include evaluating wearing, pharmacokinetics, specialty populations, repeat applications, skin abrasions, drug interactions and dose conversions. In addition, a non-clinical package comprising multiple animal safety studies has been developed, including carcinogenicity studies, long-ter
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Pharmaceuticals, Inc. (Nasdaq: CADX ) today announced that ... of its common stock at a price to the public ... of the shares, after deducting the underwriting discounts and commissions ... million.  Cadence has granted the underwriters for the offering a ...
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Nov. 26 David B. Snow,chairman & chief executive ... to address the Merrill Lynch & Co., Inc. 2007 ... presentation at Merrill Lynch headquarters, New York, will begin ... and Richard J.,Rubino, CPA, Medco,s controller and chief accounting ...
... CHICAGO, Nov. 26 All-terrain vehicles (ATVs) pose a,serious ... largest study ever,conducted of ATV injuries in children. The ... Radiological Society of North America (RSNA)., "Our experience ... be restricted," said Chetan C. Shah, M.D., radiology fellow ...
... women have a different understanding of screening mammography ... the findings of a Boston University Medical Center ... the Radiological Society of North America (RSNA). , ... ethnic and socioeconomic groups, said Nazia F. Jafri, ...
... PHILADELPHIA Researchers at the University of Pennsylvania School ... transcranial magnetic stimulation (TMS) a non-invasive technique that ... through the scalp is a safe and effective, ... major depression who have tried other treatment options without ...
... and its there in bright medical images: evidence of ... secondhand cigarette smoke. For the first time, researchers have ... but not previously detectable with medical imaging tools. ... public health efforts to restrict secondhand smoke. , ...
... FAAN, FAHA, a clinical professor of neurology at Boston ... the Framingham Heart Study, was recently awarded the Stroke ... award was presented at the AHAs recent Scientific Sessions ... Award recognizes and encourages those who actively work to ...
Cached Medicine News:Health News:Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 3Health News:Attitudes toward mammography differ across ethnicities, cultures, backgrounds 2Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:Secondhand smoke damages lungs, MRIs show 2
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Filiform Spiral Tip 12 Inch , 20 ... female thread. Available in 3,4,5 6Fr. These ... strong but flexible polymer material and have ... other brands. They are manufactured to the ...
... for stone manipulation and removal in the urinary ... Delta Wire. The revolutionary triangular shape of Delta ... largest possible wire mass. The superior mass of ... qualities of nitinol alloy, creates a basket with ...
... SILASTIC Brand Latex Foley Catheter, Smooth, ... build-up, Firm, but flexible, latex-based construction ... length - round tip with two ... (336xx) or two staggered eyes and ...
Medicine Products: